SLC7A11 and central nervous system cancer: Three criteria, including iron levels, gene expression and mutations, can be combined to assess which patients are most likely to benefit from ferroptosis; for example, SLC7A11 inhibitors may be particularly effective against certain types of gliomas that overexpress this target.